{
    "xml": "<topic id=\"PHP93587\" outputclass=\"drug\" rev=\"1.10\" type=\"drug\" namespace=\"/drugs/idelalisib\" basename=\"idelalisib\" title=\"IDELALISIB\">\n<title>IDELALISIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1348\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/idelalisib\">Idelalisib</xref>\n</p>\n<data name=\"vtmid\">27966511000001101</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP93666\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/idelalisib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Idelalisib is a protein kinase inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93669\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/idelalisib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of chronic lymphocytic leukaemia in patients who have received at least one previous therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy (in combination with rituximab)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of follicular lymphoma refractory to two lines of treatment (monotherapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily, for dose adjustment due to side effects, consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93665\" outputclass=\"importantSafetyInformation\" rev=\"1.12\" parent=\"/drugs/idelalisib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93662\" outputclass=\"cautions\" rev=\"1.8\" parent=\"/drugs/idelalisib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Active hepatitis</ph>; <ph outputclass=\"caution\">diarrhoea&#8212;symptomatic management recommended (consult product literature)</ph>; <ph outputclass=\"caution\">pneumonitis&#8212;withhold treatment (consult product literature)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93670\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/idelalisib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (idelalisib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93675\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/idelalisib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">infections</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">pneumonitis</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93663\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/idelalisib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;highly effective contraception (in addition to barrier method) required during and for one month after treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93671\" outputclass=\"pregnancy\" parent=\"/drugs/idelalisib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid (toxicity in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. </p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93661\" outputclass=\"breastFeeding\" parent=\"/drugs/idelalisib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93668\" outputclass=\"hepaticImpairment\" parent=\"/drugs/idelalisib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93679\" outputclass=\"monitoringRequirements\" parent=\"/drugs/idelalisib\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93682\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/drugs/idelalisib\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2015) that idelalisib (<i>Zydelig</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of relapsed chronic lymphocytic leukaemia in patients who are unsuitable for chemotherapy and treatment na&#239;ve patients with 17p depletion or TP53 mutation who are unsuitable for chemo-immunotherapy.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93587-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/idelalisib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101366\" title=\"Tablet\" namespace=\"/drugs/idelalisib/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1348\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/idelalisib\" title=\"Idelalisib\" count=\"1\" rel=\"link\">Idelalisib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101366\" namespace=\"/drugs/idelalisib/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP93587",
    "outputclass": "drug",
    "rev": "1.10",
    "type": "drug",
    "namespace": "/drugs/idelalisib",
    "basename": "idelalisib",
    "title": "IDELALISIB",
    "interactants": [
        {
            "id": "bnf_int_1348",
            "label": "Idelalisib"
        }
    ],
    "vtmid": "27966511000001101",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Idelalisib is a protein kinase inhibitor.",
                "html": "<p>Idelalisib is a protein kinase inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of chronic lymphocytic leukaemia in patients who have received at least one previous therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy (in combination with rituximab)",
                        "html": "Treatment of chronic lymphocytic leukaemia in patients who have received at least one previous therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy (in combination with rituximab)"
                    },
                    {
                        "textContent": "Treatment of follicular lymphoma refractory to two lines of treatment (monotherapy)",
                        "html": "Treatment of follicular lymphoma refractory to two lines of treatment (monotherapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg twice daily, for dose adjustment due to side effects, consult product literature.",
                        "html": "<p>150&#8239;mg twice daily, for dose adjustment due to side effects, consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Active hepatitis",
                "html": "Active hepatitis"
            },
            {
                "type": "cautions",
                "textContent": "diarrhoea&#8212;symptomatic management recommended (consult product literature)",
                "html": "diarrhoea&#8212;symptomatic management recommended (consult product literature)"
            },
            {
                "type": "cautions",
                "textContent": "pneumonitis&#8212;withhold treatment (consult product literature)",
                "html": "pneumonitis&#8212;withhold treatment (consult product literature)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (idelalisib).",
                "html": "<p>Appendix 1 (idelalisib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infections",
                        "html": "infections",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pneumonitis",
                        "html": "pneumonitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;highly effective contraception (in addition to barrier method) required during and for one month after treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;highly effective contraception (in addition to barrier method) required during and for one month after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid (toxicity in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid (toxicity in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. </p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in hepatic impairment.",
                "html": "<p>Manufacturer advises caution in hepatic impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function&#8212;consult product literature.",
                "html": "<p>Monitor liver function&#8212;consult product literature.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (March 2015) that idelalisib (Zydelig ) is accepted for restricted use within NHS Scotland for the treatment of relapsed chronic lymphocytic leukaemia in patients who are unsuitable for chemotherapy and treatment na&#239;ve patients with 17p depletion or TP53 mutation who are unsuitable for chemo-immunotherapy.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (March 2015) that idelalisib (<i>Zydelig</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of relapsed chronic lymphocytic leukaemia in patients who are unsuitable for chemotherapy and treatment na&#239;ve patients with 17p depletion or TP53 mutation who are unsuitable for chemo-immunotherapy.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101366",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1348",
                "label": "Idelalisib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101366",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}